Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 100 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Advanced HR+/HER2- Breast Cancer Clear all
Recruiting Phase 1Phase 2 Interventional

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366
View directory record Official record
Conditions
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer
Interventions
Rina-S, Carboplatin, Bevacizumab, Pembrolizumab
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 28, 2026, 2:41 PM EDT
Completed Phase 2 Interventional

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

NCT05963984
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
Interventions
Samuraciclib, Fulvestrant
Drug
Lead sponsor
Carrick Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Ocala, Florida • Baltimore, Maryland • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 28, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant

NCT04224272
View directory record Official record
Conditions
HER2+/HR+ Breast Cancer
Interventions
ZW25 (Zanidatamab), Palbociclib, Fulvestrant
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Santa Monica, California • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 2:41 PM EDT
Completed No phase listed Observational

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

NCT04498481
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 28, 2026, 2:41 PM EDT
Recruiting Phase 1 Interventional

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

NCT07604571
View directory record Official record
Conditions
Advanced HR+/HER2- Breast Cancer
Interventions
IEV407, Fulvestrant, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
New Haven, Connecticut • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 28, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

NCT02791334
View directory record Official record
Conditions
Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer, Breast Cancer (HR+HER2-)
Interventions
LY3300054, Ramucirumab, Abemaciclib, Merestinib, LY3321367
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Nashville, Tennessee • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Sep 28, 2026, 2:41 PM EDT
Completed No phase listed Observational Results available

Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy

NCT04394247
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 28, 2026, 2:41 PM EDT
Recruiting Phase 3 Interventional

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

NCT07205822
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Largo, Florida • Fort Wayne, Indiana • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 28, 2026, 2:41 PM EDT
Terminated Phase 1 Interventional

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

NCT05194072
View directory record Official record
Conditions
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
Interventions
Felmetatug Vedotin, Pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Aurora, Colorado • Denver, Colorado • Celebration, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 28, 2026, 2:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AVZO-021 in Patients With Advanced Solid Tumors

NCT05867251
View directory record Official record
Conditions
Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
AVZO-021, Palbociclib, Fulvestrant, Letrozole, Ribociclib, Abemaciclib, Carboplatin, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
11
States / cities
New Haven, Connecticut • Sarasota, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 28, 2026, 2:41 PM EDT
Recruiting Phase 3 Interventional

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

NCT07174336
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane, Fulvestrant
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
127
States / cities
Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 109 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 28, 2026, 2:41 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

NCT05169567
View directory record Official record
Conditions
Breast Neoplasm, Neoplasm Metastasis
Interventions
Abemaciclib, Fulvestrant, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
60
States / cities
Phoenix, Arizona • Springdale, Arkansas • Fullerton, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 28, 2026, 2:41 PM EDT
Completed No phase listed Observational

A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib

NCT07363434
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 28, 2026, 2:41 PM EDT
Recruiting Phase 1 Interventional

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775
View directory record Official record
Conditions
Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer
Interventions
BBO-10203, Trastuzumab, Fulvestrant, Ribociclib, FOLFOX, Bevacizumab
Drug
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 28, 2026, 2:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

NCT06998407
View directory record Official record
Conditions
HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
Interventions
AVZO-021, Fulvestrant, Letrozole, AVZO-023
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
16
States / cities
Los Angeles, California • New Haven, Connecticut • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 28, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

A Study of PRT2527 in Participants With Advanced Solid Tumors

NCT05159518
View directory record Official record
Conditions
Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification
Interventions
PRT2527
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Denver, Colorado • Celebration, Florida • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Sep 28, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

NCT02437318
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Alpelisib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
34
States / cities
Chandler, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 28, 2026, 2:41 PM EDT
Terminated Phase 3 Interventional

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

NCT03326674
View directory record Official record
Conditions
Breast Cancer
Interventions
Tesetaxel and Capecitabine, Capecitabine
Drug
Lead sponsor
Odonate Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
90
States / cities
Chandler, Arizona • Goodyear, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 28, 2026, 2:41 PM EDT
Completed No phase listed Observational

Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal

NCT07223476
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
1,926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 28, 2026, 2:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

NCT04505826
View directory record Official record
Conditions
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
Interventions
OP-1250
Drug
Lead sponsor
Olema Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • Deerfield Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 28, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

NCT03056755
View directory record Official record
Conditions
Breast Cancer
Interventions
Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
25
States / cities
Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 28, 2026, 2:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

NCT05985655
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)
Interventions
GTAEXS617, SoC
Drug
Lead sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Grand Rapids, Michigan • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 28, 2026, 2:41 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer

NCT05963997
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
Interventions
Samuraciclib, Elacestrant Dihydrochloride
Drug
Lead sponsor
Carrick Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Chicago, Illinois • Boston, Massachusetts • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 28, 2026, 2:41 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

NCT07318805
View directory record Official record
Conditions
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
Interventions
PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Duarte, California • Grand Rapids, Michigan • Long Island City, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 28, 2026, 2:41 PM EDT